Showing results (231-240 of 321) with videos related to

Sort By:
Pageof 33
Rheumatology and Therapy|December 7, 2020
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X TrialAtul Deodhar, Philip Mease, Proton Rahman, et al.
Annals of the Rheumatic Diseases|September 15, 2012
Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumabCarrie L Wagner, Sudha Visvanathan, Michael Elashoff, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 24, 2012
Evaluation of clinical outcomes and renal vascular pathology among patients with lupusClaire Barber, Andrew Herzenberg, Ellie Aghdassi, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Rheumatology (Oxford, England)|September 20, 2022
Individual participant data meta-analysis of metabolomics on sustained knee pain in primary osteoarthritis patientsChristie A Costello, Jason S Rockel, Ming Liu, et al.
The Journal of Rheumatology|May 3, 2020
Phenylalanine Is a Novel Marker for Radiographic Knee Osteoarthritis Progression: The MOST StudyGuangju Zhai, Xianbang Sun, Edward W Randell, et al.
The Lancet. Rheumatology|January 25, 2024
Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 studyIain B McInnes, Philip J Mease, Alan J Kivitz, et al.
The Journal of Rheumatology|May 23, 2002
The rate and pattern of organ damage in late onset systemic lupus erythematosusPeter Maddison, Vernon Farewell, David Isenberg, et al.
Rheumatology and Therapy|December 19, 2025
Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X TrialsJohn D Reveille, Martin Rudwaleit, Proton Rahman, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
Pageof 33